AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.
about
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsComparison of AMG 416 and cinacalcet in rodent models of uremiaClinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States.Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisEmerging drugs for secondary hyperparathyroidism.The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.The challenge of controlling phosphorus in chronic kidney disease.Advances in pharmacotherapy for secondary hyperparathyroidism.Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.Management of secondary hyperparathyroidism: how and why?Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Etelcalcetide: First Global Approval.Etelcalcetide for the treatment of secondary hyperparathyroidism.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis PatientsPopulation pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.Parathyroidectomy: Complex Decisions about a Complex Procedure.A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
P2860
Q34385273-CAE53E1F-6691-4D37-8063-AD028E6CEA3EQ35177929-DEA6C128-1091-4A2F-84F8-6B9E037F471FQ36432849-FCBD4356-B215-4F91-8FD5-DCDA37E1BC0EQ37069993-21630BEB-5AFE-4B1A-ABC0-9495B5E16FB5Q37595124-0AD99238-072E-4783-A1B4-05C7A049DA0AQ38363615-029195AF-A133-437E-A686-21C577086182Q38370743-58FFCD4B-0475-4908-9215-F15B2D9A6366Q38377286-871618A2-81A5-4847-B771-1ADF1EDA3E37Q38544533-AB52E9D7-A567-4527-91C5-976E41ED1EF7Q38576402-0C74D6FC-40A7-45F2-BEB8-942FCCFA1ADFQ38610957-40B048C1-2927-4096-9B0F-D48DEE0E96A5Q38775426-4BF00F97-BC48-4AA8-93D1-E77A4B15648DQ38824573-DDA87F56-F0F6-45B0-9F08-748A01EF2345Q38828618-19FD4D24-158E-4215-BE95-71148472690BQ39024226-EFBCA9C7-DC6E-40D6-A3BA-8BF77C17EF38Q39170853-BBD004AB-9CED-4D4B-A188-678CEBADB538Q39220825-FAF3E449-AC9C-4366-8159-A3005134B3C6Q39379162-638153A3-B4CE-49D3-9E58-961123A803DEQ39949155-5B5282AF-E7C2-420B-8620-0B2BD678506FQ40479039-716B8F16-6E32-4C89-A803-2A85D3552172Q41592465-07CA37D3-60E1-4A63-B748-E630FA3D523CQ42430335-A6A3B977-37C6-499F-A242-64700F74AB8FQ47102093-DB682D83-4F60-4F1F-863B-5A521F89DEE1Q49332215-F9ADDB3A-A3F9-49D4-8999-AD73D4B366CFQ50024790-DFE84E43-AC91-43E2-B50C-1DAF6FE34CD2Q50077724-CFAAC3E4-A9E3-4C4A-B405-3852C53AA42FQ55413395-B3986D19-313C-4299-8407-EA6EA0A5F583
P2860
AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
AMG 416 (velcalcetide) is a no ...... tudy in hemodialysis patients.
@en
AMG 416
@nl
type
label
AMG 416 (velcalcetide) is a no ...... tudy in hemodialysis patients.
@en
AMG 416
@nl
prefLabel
AMG 416 (velcalcetide) is a no ...... tudy in hemodialysis patients.
@en
AMG 416
@nl
P2093
P356
P1433
P1476
AMG 416 (velcalcetide) is a no ...... tudy in hemodialysis patients.
@en
P2093
Andrew Vick
David A Power
Geoffrey A Block
Gregory Bell
Karen Pickthorn
Kevin J Martin
Saling Huang
P2888
P304
P356
10.1038/KI.2013.289
P407
P50
P577
2013-07-31T00:00:00Z
P5875
P6179
1027980026